LipoScience, Inc., which provides NMRI testing for LDL particles in management of cardiovascular disease risk, filed on Thursday with the SEC to raise up to $86 million in an initial public offering. The Raleigh, NC-based company, which was founded in 1997 and booked $41 million in sales for the 12 months ended March 31, 2011, plans to list on the NASDAQ. Barclays Capital, UBS Investment Bank, and Piper Jaffray are the lead underwriters on the deal. No pricing terms were disclosed.
